Pfizer is bringing back a cancer drug it pulled from the U.S. market over safety concerns in 2010--but the second iteration carries a higher cost, in the latest sign of the industry’s pricing power.
from WSJ.com: US Business http://ift.tt/2eri5Vc
via IFTTT
No comments:
Post a Comment